Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > COMMENTARY
COMMENTARY
- Top Wholesalers Cut Costs to Offset Declines in Gross Profits
December 5, 2005
- Importance of Framing
November 21, 2005
- A Cluster of Diseases - Metabolic Syndrome: Reflecting Aging Society
November 7, 2005
- A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -1-
October 31, 2005
- Commentary 2005 Will Be "Year 1" of Japanese Drug Industry Reorganization
October 17, 2005
- COMMENTARY 2 articles
October 10, 2005
- COMMENTARY 6 articles
September 19, 2005
- Where Will the Japanese Pharmaceutical Industry Drift? - From "The Sky Is the Limit" to the Abyss -
August 29, 2005
- COMMENTARY 5 articles
August 8, 2005
- 2 Rosai Hospitals Start Prescriptions by the Generic Name
July 25, 2005
- COMMENTARY 6 articles
July 25, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (3)
July 4, 2005
- Former Reviewers' Interviews Make OPIR Report Exciting
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
- Special Contribution
May 16, 2005
- Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
- PRTM Shows Results of Investigational Drug Survey
March 14, 2005
- ＜Special Comtribution＞
March 7, 2005
- ＜Special Comtribution＞
March 7, 2005
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…